On August 28, Cytokinetics rose 6.74% in pre-market trading, trading at $81.055/share, with turnover of $392,600.

The move was driven by multiple positive catalysts: the company's pivotal Phase 3 Acacia-HCM study results were formally presented at the European Society of Cardiology Annual Meeting Hot Line session and simultaneously published in the New England Journal of Medicine. Additionally, Cytokinetics announced plans to submit a supplemental New Drug Application to the U.S. FDA in Q4 for Aficamten to treat symptomatic non-obstructive hypertrophic cardiomyopathy (nHCM) in adults.

The Acacia-HCM trial previously demonstrated positive topline results in early May, meeting dual primary endpoints of KCCQ-CSS and maximal exercise capacity at Week 36, with no new safety signals identified. RBC Capital Markets has estimated that if the nHCM indication is approved, it could represent approximately $1.3 billion in incremental U.S. revenue for Myqorzo. The publication in a top-tier journal and regulatory filing timeline reinforce Cytokinetics' position in the cardiovascular precision therapy space.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)